Columbia Solid Tumor (CSTP) Subpanels
Purpose
Detects commonly mutated genes in the following disease classes: lung, colorectal/pancreatic, cholangiocarcinoma, GIST, glioma, gynecological, histiocytic, melanoma, urothelial and thyroid.
CPT Codes
81445, 81479, 88381
Methodology
Next Generation Sequencing (NGS) of DNA
Turnaround Time
14 days; 12 days for Lung Panel
Specimen Accepted
Formalin-fixed paraffin embedded (FFPE) or frozen tissue, Cytology specimens in CytoLyt solution, whole blood or bone marrow in EDTA, or DNA extracted from a CLIA laboratory
Available Subpanels
Lung Panel
BRAF(NM_004333 e11,15); EGFR(NM_005228 e3,7,12,15,18-21); ERBB2(NM_004448 e8,17,19-21); KEAP1 (NM_012289.4 e2-6); KRAS(NM_004985 e2-4); MET(NM_001127500 e2,14,16,18,19); PIK3CA(NM_006218 e2,3,5,7,8,10,14,19,21), POLD1(NM_002691 e6-10,15-20,24), POLE(NM_006231 e1,2,9,11,13,14,20,21,25,26); STK11(NM_000455 e1-9, full coding sequence); TP53(NM_000546 e2,4-10)
Colorectal/Pancreatic Panel
BRAF(NM_004333 e11,15); ERBB2(NM_004448 e8,17,19-21); KRAS(NM_004985 e2-4); NRAS(NM_002524 e2-4); PIK3CA(NM_006218 e2,3,5,7,8,10,14,19,21); POLD1(NM_002691 e6-10,15-20,24); POLE(NM_006231 e1,2,9,11,13,14,20,21,25,26); TP53(NM_000546 e2,4-10)
Cholangiocarcinoma Panel
BRAF(NM_004333 e11,15); ERBB2(NM_004448 e8,17,19-21); FGFR2(NM_000141 e7,9,12); IDH1(NM_005896 e4); IDH2(NM_002168 e4); KRAS(NM_004985 e2-4); NRAS(NM_002524 e2-4); POLD1(NM_002691 e6-10,15-20,24); POLE(NM_006231 e1,2,9,11,13,14,20,21,25,26); TP53(NM_000546 e2,4-10)
GIST Panel
KIT(NM_000222 e8,9,10,11,13,14,15,17,18), PDGFRA(NM_006206 e12,14,15,18)
Glioma Panel
BRAF(NM_004333 e11,15); EGFR(NM_005228 e3,7,12,15,18-21); FGFR1(NM_023110 e4,7,12,14); FGFR2(NM_000141 e7,9,12); FGFR3(NM_000142 e7,9,14,16,18); H3F3A(NM_002107 e2); HIST1H3B(NM_003537 e1); IDH1(NM_005896 e4); IDH2(NM_002168 e4); PIK3CA(NM_006218 e2,3,5,7,8,10,14,19,21); PTEN(NM_000314 e1-9); TERT(promoter, NM_198253 5’UTR); TP53(NM_000546 e2,4-10)
Gynecological Panel
AKT1(NM_005163 e3); BRAF(NM_004333 e11,15); CTNNB1(NM_001904 e3,7,8); ERBB2(NM_004448 e8,17,19-21); KRAS(NM_004985 e2-4); PIK3CA(NM_006218 e2,3,5,7,8,10,14,19,21); POLD1(NM_002691 e6-10,15-20,24); POLE(NM_006231 e1,2,9,11,13,14,20,21,25,26); PTEN(NM_000314 e1-9); TERT(promoter, NM_198253 5’UTR); TP53(NM_000546 e2,4-10)
Histiocytic Panel
ARAF(NM_001654 e7); BRAF(NM_004333 e11,15); KRAS(NM_004985 e2-4); MAP2K1(NM_002755 e2,3,6,7,11); NRAS(NM_002524 e2-4); PIK3CA(NM_006218 e2,3,5,7,8,10,14,19,21)
Melanoma Panel
BRAF(NM_004333 e11,15); CYSLTR2(NM_001308465 e5); EIF1AX(NM_001412 e1,2,6); GNAQ(NM_002072 e2,4,5); GNA11(NM_002067 e4-5); IDH1(NM_005896 e4); KIT(NM_000222 e8,9,10,11,13,14,15,17,18); KRAS(NM_004985 e2-4); HRAS(NM_005343 e2-4); NRAS(NM_002524 e2-4); PLCB4(NM_000933 e20); RAC1(NM_006908 e2); SF3B1(NM_012433 e14); SRSF2(NM_003016 e1); TERT(promoter, NM_198253 5’UTR); TP53(NM_000546 e2,4-10)
Urothelial Panel
AKT1(NM_005163 e3); CDKN2A(NM_000077 e2); ERBB2(NM_004448 e8,17,19-21); FGFR1(NM_023110 e4,7,12,14); FGFR2(NM_000141 e7,9,12); FGFR3(NM_000142 e7,9,14,16,18); HRAS(NM_005343 e2-4); KRAS(NM_004985 e2-4); NRAS(NM_002524 e2-4); PIK3CA(NM_006218 e2,3,5,7,8,10,14,19,21); TERT(promoter, NM_198253 5’UTR); TP53(NM_000546 e2,4-10)
Thyroid Panel
AKT1(NM_005163 e3); BRAF(NM_004333 e11,15); CTNNB1(NM_001904 e3,7,8); EIF1AX(NM_001412 e1,2,6); GNAS(NM_000516 e8,9); HRAS(NM_005343 e2-4); KRAS(NM_004985 e2-4); NRAS(NM_002524 e2-4); PIK3CA(NM_006218 e2,3,5,7,8,10,14,19,21); PTEN(NM_000314 e1-9); RET(NM_020975 e10,11,13,15,16); TERT(promoter, NM_198253 5’UTR); TP53(NM_000546 e2,4-10); TSHR(NM_000369 e9-10)